<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Res</journal-id><journal-id journal-id-type="publisher-id">cvrese</journal-id><journal-id journal-id-type="hwp">cardiovascres</journal-id><journal-title-group><journal-title>Cardiovascular Research</journal-title></journal-title-group><issn pub-type="ppub">0008-6363</issn><issn pub-type="epub">1755-3245</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1093/cvr/cvp334</article-id><article-id pub-id-type="publisher-id">cvp334</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Ischaemic preconditioning improves proteasomal activity and increases the degradation of &#x003b4;PKC during reperfusion</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Churchill</surname><given-names>Eric N.</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>Julio C.</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Brum</surname><given-names>Patricia C.</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Szweda</surname><given-names>Luke I.</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mochly-Rosen</surname><given-names>Daria</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Department of Chemical and Systems Biology</addr-line>, <institution>Stanford University School of Medicine</institution>, <addr-line>Stanford, CA 94305-5174</addr-line>, <country>USA</country></aff><aff id="af2"><label>2</label><addr-line>School of Physical Education and Sport</addr-line>, <institution>University of S&#x000e3;o Paulo</institution>, <addr-line>S&#x000e3;o Paulo, SP 05508-900</addr-line>, <country>Brazil</country></aff><aff id="af3"><label>3</label><addr-line>Free Radical Biology and Aging Research Program</addr-line>, <institution>Oklahoma Medical Research Foundation</institution>, <addr-line>825 N.E. 13th Street, Oklahoma City, OK 73104</addr-line>, <country>USA</country></aff><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Tel: <phone>+1 650 725 7720</phone>, Fax: <fax>+1 650 723 2253</fax>, Email: <email>mochly@stanford.edu</email></corresp></author-notes><pub-date pub-type="ppub"><day>15</day><month>1</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>10</day><month>10</month><year>2009</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>10</month><year>2009</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>85</volume><issue>2</issue><fpage>385</fpage><lpage>394</lpage><history><date date-type="received"><day>4</day><month>5</month><year>2009</year></date><date date-type="rev-recd"><day>15</day><month>9</month><year>2009</year></date><date date-type="accepted"><day>28</day><month>9</month><year>2009</year></date></history><permissions><copyright-statement>Published on behalf of the European Society of Cardiology. All rights reserved. &#x000a9; The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.</copyright-statement><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/"><license-p>The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org.</license-p></license></permissions><abstract><sec><title>Aims</title><p>The response of the myocardium to an ischaemic insult is regulated by two highly homologous protein kinase C (PKC) isozymes, &#x003b4; and &#x003b5;PKC. Here, we determined the spatial and temporal relationships between these two isozymes in the context of ischaemia/reperfusion (I/R) and ischaemic preconditioning (IPC) to better understand their roles in cardioprotection.</p></sec><sec><title>Methods and results</title><p>Using an <italic>ex vivo</italic> rat model of myocardial infarction, we found that short bouts of ischaemia and reperfusion prior to the prolonged ischaemic event (IPC) diminished &#x003b4;PKC translocation by 3.8-fold and increased &#x003b5;PKC accumulation at mitochondria by 16-fold during reperfusion. In addition, total cellular levels of &#x003b4;PKC decreased by 60 &#x000b1; 2.7% in response to IPC, whereas the levels of &#x003b5;PKC did not significantly change. Prolonged ischaemia induced a 48 &#x000b1; 11% decline in the ATP-dependent proteasomal activity and increased the accumulation of misfolded proteins during reperfusion by 192 &#x000b1; 32%; both of these events were completely prevented by IPC. Pharmacological inhibition of the proteasome or selective inhibition of &#x003b5;PKC during IPC restored &#x003b4;PKC levels at the mitochondria while decreasing &#x003b5;PKC levels, resulting in a loss of IPC-induced protection from I/R. Importantly, increased myocardial injury was the result, in part, of restoring a &#x003b4;PKC-mediated I/R pro-apoptotic phenotype by decreasing pro-survival signalling and increasing cytochrome <italic>c</italic> release into the cytosol.</p></sec><sec><title>Conclusion</title><p>Taken together, our findings indicate that IPC prevents I/R injury at reperfusion by protecting ATP-dependent 26S proteasomal function. This decreases the accumulation of the pro-apoptotic kinase, &#x003b4;PKC, at cardiac mitochondria, resulting in the accumulation of the pro-survival kinase, &#x003b5;PKC.</p></sec></abstract><kwd-group><kwd>Cardioprotection</kwd><kwd>Ischaemia/reperfusion</kwd><kwd>Apoptosis</kwd><kwd>Proteasome</kwd><kwd>PKC</kwd><kwd>Ischaemic preconditioning</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>primary-review-time</meta-name><meta-value><bold>Time for primary review: 24 days</bold></meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><label>1.</label><title>Introduction</title><p>Myocardial ischaemia and reperfusion (I/R)-induced damage is associated with both apoptotic and necrotic cell death.<sup><xref ref-type="bibr" rid="CVP334C1">1</xref></sup> We have shown this to be dependent on translocation of delta protein kinase C (&#x003b4;PKC) to cardiac mitochondria where it inhibits mitochondrial function.<sup><xref ref-type="bibr" rid="CVP334C2">2</xref>&#x02013;<xref ref-type="bibr" rid="CVP334C4">4</xref></sup> Inhibition of &#x003b4;PKC with the selective peptide inhibitor, &#x003b4;V<sub>1&#x02013;1</sub>, protects the heart from ischaemic injury.<sup><xref ref-type="bibr" rid="CVP334C4">4</xref>,<xref ref-type="bibr" rid="CVP334C5">5</xref></sup> Ischaemic preconditioning (IPC) observed in animals and humans<sup><xref ref-type="bibr" rid="CVP334C6">6</xref>&#x02013;<xref ref-type="bibr" rid="CVP334C8">8</xref></sup> protects the heart from reperfusion injury by activating pro-survival kinases,<sup><xref ref-type="bibr" rid="CVP334C9">9</xref>&#x02013;<xref ref-type="bibr" rid="CVP334C11">11</xref></sup> preventing apoptosis<sup><xref ref-type="bibr" rid="CVP334C12">12</xref>,<xref ref-type="bibr" rid="CVP334C13">13</xref></sup> and necrosis<sup><xref ref-type="bibr" rid="CVP334C2">2</xref>,<xref ref-type="bibr" rid="CVP334C4">4</xref></sup> preserving mitochondrial function,<sup><xref ref-type="bibr" rid="CVP334C14">14</xref>,<xref ref-type="bibr" rid="CVP334C15">15</xref></sup> and reducing ROS generation.<sup><xref ref-type="bibr" rid="CVP334C16">16</xref></sup> Many of these effects are afforded, at least in part, through activation and translocation of &#x003b5;PKC to cardiac mitochondria,<sup><xref ref-type="bibr" rid="CVP334C17">17</xref>&#x02013;<xref ref-type="bibr" rid="CVP334C20">20</xref></sup> resulting in diminished apoptosis and necrosis.<sup><xref ref-type="bibr" rid="CVP334C12">12</xref>,<xref ref-type="bibr" rid="CVP334C21">21</xref></sup></p><p>Interestingly, activation of &#x003b4;PKC is also required for both opioid<sup><xref ref-type="bibr" rid="CVP334C22">22</xref></sup> and IPC-mediated protection.<sup><xref ref-type="bibr" rid="CVP334C23">23</xref>,<xref ref-type="bibr" rid="CVP334C24">24</xref></sup> We showed that activation of &#x003b4;PKC is cardioprotective provided there is sufficient time allowed for &#x003b5;PKC activation.<sup><xref ref-type="bibr" rid="CVP334C25">25</xref></sup> Furthermore, &#x003b5;PKC is activated by ROS during IPC,<sup><xref ref-type="bibr" rid="CVP334C26">26</xref></sup> whereas &#x003b4;PKC plays a role in ROS generation.<sup><xref ref-type="bibr" rid="CVP334C27">27</xref></sup> Therefore, although both PKC isozymes play a role in IPC, the mechanism by which the pro-survival kinase (&#x003b5;PKC) and the pro-death kinase (&#x003b4;PKC) interact is not known. Here, we present evidence of a novel mechanism in which the proteasome alters the ratio between &#x003b4;PKC and &#x003b5;PKC, thereby regulating myocardial viability following I/R.</p></sec><sec id="s2" sec-type="methods"><label>2.</label><title>Methods</title><sec id="s2a"><label>2.1</label><title>Materials</title><p>All antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Lactacystin, LLVY-AMC, epoxomycin, and MG-132 were from Biomol (Plymouth Meeting, PA). &#x003b5;V<sub>1&#x02013;2</sub><sup><xref ref-type="bibr" rid="CVP334C28">28</xref></sup> and &#x003c8;&#x003b5;RACK<sup><xref ref-type="bibr" rid="CVP334C29">29</xref></sup> conjugated to TAT were made by Anaspec, San Jose, CA. This study conforms with the <italic>Guide for the Care and Use of Laboratory Animals</italic> published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).</p></sec><sec id="s2b"><label>2.2</label><title>Isolated perfused rat heart model and measurement of tissue necrosis</title><p>All procedures were carried out as described.<sup><xref ref-type="bibr" rid="CVP334C2">2</xref></sup> All animal protocols were approved by the Institutional Animal Care and Use Committee of Stanford University.</p></sec><sec id="s2c"><label>2.3</label><title>Cellular fractionation and western blotting</title><p>Isolated hearts were homogenized in 210 mM mannitol, 70 mM sucrose, 1 mM EDTA, and 5 mM MOPS, pH = 7.4. After filtering through cheesecloth and a 5 min centrifugation at 800&#x000d7;g, the supernatant was centrifuged (10 000&#x000d7;g; 10 min) to obtain the mitochondrial pellet and the cytosolic extract (supernatant). This technique provides a mitochondrial fraction with only traces of sarcolemmal and plasma membrane contamination.<sup><xref ref-type="bibr" rid="CVP334C30">30</xref></sup> Western blot analysis used polyclonal &#x003b5;PKC, &#x003b4;PKC, p-Akt, Akt, and cytochrome <italic>c</italic> antibodies, was normalized to ANT (mitochondria) and GAPDH (total and cytosolic homogenates) and was expressed as percent control.</p></sec><sec id="s2d"><label>2.4</label><title>Assay of proteasome activity</title><p>Chymotrypsin-like activity of the proteasome was assayed using the fluorogenic peptide Suc-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (25 &#x003bc;M, LLVY-MCA) in a microtiter plate (50 &#x003bc;g protein) with 200 &#x003bc;l of 10 mM MOPS, pH 7.4. Assays were carried out in the absence and presence of 2.5 mM ATP and 5.0 mM Mg<sup>2+</sup> with the difference attributed to ATP-dependent proteasome activity. The rate of fluorescent product formation was measured with excitation and emission wavelengths of 350 and 440 nm, respectively. In order to block proteasome activity during the experimental protocol, 2.0 &#x003bc;M lactacystin was perfused during the preconditioning protocol and the first 10 min of reperfusion.</p></sec><sec id="s2e"><label>2.5</label><title>Slot blot analysis of cellular misfolded proteins</title><p>Heart tissue homogenate (25 &#x003bc;g protein) was normalized and slot blotted onto PVDF membrane (Millipore, Bedford, MA, USA) and membranes were washed three times with 0.05% Tween 20, 10 mM Tris, pH 7.5, 100 mM NaCl (T-TBS) and blocked in T-TBS + 5% milk. After 4 h of incubation with an anti-soluble oligomer antibody (Biosource International, Camarillo, CA), an antibody that recognizes misfolded proteins,<sup><xref ref-type="bibr" rid="CVP334C31">31</xref></sup> proteins were visualized as in the western blot analysis. Sample loading was normalized by Ponceau staining.</p></sec><sec id="s2f"><label>2.6</label><title>Analysis of cellular ATP levels</title><p>ATP determination was carried out using the Molecular Probes luciferase-based ATP determination kit (Kit# A22066). In brief, 100 &#x003bc;g of protein was incubated in a 96-well plate with 50 &#x003bc;M luciferin and 1.25 &#x003bc;g/mL luciferase in a Tris-based 1X reaction buffer containing DTT. ATP was measured after 5 min using a luminometer (560 nm at room temperature) using a standard curve of known ATP concentrations.</p></sec><sec id="s2g"><label>2.7</label><title>Statistics</title><p>Data are represented as the mean &#x000b1; SE, and significance was determined by one-way analysis of variance with a <italic>post-hoc</italic> Tukey test or a two-tailed <italic>t</italic>-test.</p></sec></sec><sec id="s3" sec-type="results"><label>3.</label><title>Results</title><sec id="s3a"><label>3.1</label><title>IPC diminishes &#x003b4;PKC at the mitochondria and increases &#x003b5;PKC translocation</title><p>Since the mitochondria are critical sites of regulation by &#x003b4; and &#x003b5;PKC during I/R,<sup><xref ref-type="bibr" rid="CVP334C2">2</xref>&#x02013;<xref ref-type="bibr" rid="CVP334C6">6</xref>,<xref ref-type="bibr" rid="CVP334C10">10</xref>,<xref ref-type="bibr" rid="CVP334C16">16</xref>,<xref ref-type="bibr" rid="CVP334C19">19</xref>&#x02013;<xref ref-type="bibr" rid="CVP334C22">22</xref></sup> we first determined the levels of &#x003b4; and &#x003b5;PKC in this fraction. Thirty minutes of ischaemia and 60 min reperfusion (I<sub>30</sub>/R<sub>60</sub>) (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F1">1</xref>A</italic>) resulted in accumulation of &#x003b4;PKC (&#x0223c;6-fold; <italic>P</italic> &#x0003c; 0.001; <italic>n</italic> = 5) and &#x003b5;PKC (&#x0223c;9-fold; <italic>P</italic> &#x0003c; 0.05; <italic>n</italic> = 5) at the mitochondria (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F1">1</xref>B</italic>). However, after IPC, I/R-induced &#x003b4;PKC accumulation at the mitochondrial fraction was largely prevented, whereas &#x003b5;PKC translocation increased &#x0223c;2-fold higher than hearts that were not preconditioned (<italic>P</italic> &#x0003c; 0.01; <italic>n</italic> = 5) (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F1">1</xref>B</italic>). Interestingly, IPC resulted in a seven-fold greater increase in &#x003b5;PKC at cardiac mitochondria relative to &#x003b4;PKC (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F1">1</xref>B</italic>). The IPC stimulus alone (without subsequent I<sub>30</sub>/R<sub>60</sub>) (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F1">1</xref>C</italic> left panel) increased the levels of both &#x003b4;PKC and &#x003b5;PKC and caused an &#x0223c;2-fold increase in their mitochondrial levels relative to normoxic hearts (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F1">1</xref>C</italic> right panel; <italic>P</italic> &#x0003c; 0.05; <italic>n</italic> = 6).</p><fig id="CVP334F1" position="float"><label>Figure&#x000a0;1</label><caption><p>Ischaemic preconditioning decreases &#x003b4;PKC and increases &#x003b5;PKC levels at cardiac mitochondria during reperfusion. (<italic>A</italic>) Hearts were hung in Langendorff mode and treated with the listed perfusion protocols. Hearts were then removed, homogenized, fractionated, and the mitochondrial fraction was subjected to western blot analysis with antibodies against the proteins listed in the figure.&#x000a0;Values were normalized to adenine nucleotide translocase (ANT), a mitochondrial marker, and expressed as % of normoxia (N) control. (<italic>B</italic>) Western blot analysis of mitochondrial protein showing that 30 min of ischaemia followed by 60 min of reperfusion (I<sub>30</sub>R<sub>60</sub>) resulted in translocation of &#x003b4;PKC to mitochondria (six-folds increase; <italic>P</italic> &#x0003c; 0.05 vs. N), which was blocked when hearts were preconditioned (IPC) before the global ischaemic event (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub>). Likewise, &#x003b5;PKC association with cardiac mitochondria increased &#x0223c;7-folds during I<sub>30</sub>R<sub>60</sub> (<italic>P</italic> &#x0003c; 0.05 vs. N), but in contrast to &#x003b4;PKC, IPC prior to I/R further increased translocation of &#x003b5;PKC to 16-folds over the levels seen in normoxic hearts (<italic>P</italic> &#x0003c; 0.05 vs. N and I<sub>30</sub>R<sub>60</sub>). (<italic>C</italic>) Western blot analyses showing that the IPC stimulus alone (without I<sub>30</sub>R<sub>60</sub>) significantly increased translocation of &#x003b4;PKC (<italic>P</italic> &#x0003c; 0.05 vs. N) and &#x003b5;PKC translocation (<italic>P</italic> &#x0003c; 0.05 vs. N) to the mitochondria. *<italic>P</italic> &#x0003c; 0.05 vs. N, &#x02021;<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub>) Translocation of &#x003b4;PKC and &#x003b5;PKC to the mitochondria were analysed by one-way analysis of variance with a post-hoc Tukey test. Mitochondrial PKC levels were analysed by Student's <italic>t</italic>-test.</p></caption><graphic xlink:href="cvp33401"/></fig></sec><sec id="s3b"><label>3.2</label><title>Total cellular levels of &#x003b4;PKC are greatly diminished by IPC</title><p>To determine whether the changes in the mitochondrial levels of &#x003b4; and &#x003b5;PKC reflect changes in the cellular levels of these kinases, we next determined the levels of both &#x003b5;PKC and &#x003b4;PKC in total cardiac extracts. I<sub>30</sub>/R<sub>60</sub> alone did not affect the overall levels of &#x003b4;PKC or &#x003b5;PKC vs. normoxia (N; <italic>n</italic> = 4; <italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F2">2</xref></italic>). However, after IPC followed by ischaemia, &#x003b4;PKC levels decreased by 33% (vs. N, <italic>P</italic> &#x0003c; 0.05; <italic>n</italic> = 4), whereas &#x003b5;PKC levels did not. Therefore, the reduction in &#x003b4;PKC translocation to the mitochondria (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F1">1</xref>B</italic>) appears to be associated with diminished protein levels, and this effect is selective and does not seem to affect &#x003b5;PKC translocation.</p><fig id="CVP334F2" position="float"><label>Figure&#x000a0;2</label><caption><p>Diminished mitochondrial levels of &#x003b4;PKC following IPC are due to decreased cellular levels of the isozyme. Hearts were hung in Langendorff mode and treated with the listed perfusion protocols in <italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F1">1</xref></italic>. Hearts were then removed, and homogenized, and the total homogenate was subjected to western blot analysis with antibodies against the proteins listed in the figure.&#x000a0;Values were normalized to glyceraldehyde phosphate dehydrogenase (GAPDH), a cytosolic protein, and expressed as %N. I<sub>30</sub>R<sub>60</sub> had no significant effect on total levels of either &#x003b4;PKC or &#x003b5;PKC. However, IPC before the global ischaemic event decreased the overall levels of &#x003b4;PKC by &#x0223c;80% (<italic>P</italic> &#x0003c; 0.05 vs. N), but not &#x003b5;PKC levels. *<italic>P</italic> &#x0003c; 0.05 vs. Normoxia and &#x02021;<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub>. Cellular &#x003b4;PKC and &#x003b5;PKC levels were analysed by one-way analysis of variance with a post-hoc Tukey test.</p></caption><graphic xlink:href="cvp33402"/></fig></sec><sec id="s3c"><label>3.3</label><title>IPC-induced proteasomal degradation of &#x003b4;PKC diminished its translocation to cardiac mitochondria with a concurrent increase in &#x003b5;PKC translocation to this fraction</title><p>&#x003b4;PKC has been shown to be degraded by the 26S proteasome.<sup><xref ref-type="bibr" rid="CVP334C29">29</xref></sup> Declines in ATP levels during ischaemia result in the disassembly of the 26S proteasome into the 20S form.<sup><xref ref-type="bibr" rid="CVP334C32">32</xref></sup> In contrast, IPC reduces ischaemia-mediated declines in ATP levels.<sup><xref ref-type="bibr" rid="CVP334C8">8</xref>,<xref ref-type="bibr" rid="CVP334C33">33</xref></sup> We therefore determined whether the loss in &#x003b4;PKC levels following IPC prior to I/R relates to preservation of the 26S proteasome activity. ATP Mg<sup>2+</sup>-stimulated peptidase activity is a reflection of the relative level of the 26S proteasome. Ischaemia induced a 45% decline in ATP-dependent proteasomal activity (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref>B</italic>) that was associated with an &#x0223c;3-fold increase in the accumulation of misfolded proteins during reperfusion (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref>C</italic>). IPC prevented the ischaemia-mediated declines in proteasomal activity and reduced the levels of misfolded proteins (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref>B</italic> and <italic>C</italic>; <italic>P</italic> &#x0003c; 0.05; <italic>n</italic> = 4). Furthermore, ATP levels correlated with proteasomal activity; ATP levels diminished during ischaemia/reperfusion and IPC significantly prevented this decline (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref>D</italic>).</p><fig id="CVP334F3" position="float"><label>Figure&#x000a0;3</label><caption><p>Effect of preconditioning on ischaemia-induced loss in ATP-dependent proteasome activity. (<italic>A</italic>) Cytosolic extracts were prepared from hearts exposed to 70 min of normoxic perfusion (N), 30 min of ischaemia (I<sub>30</sub>), or three cycles of preconditioning (5 min ischaemia and 5 min reperfusion) followed by 30 min of ischaemia (I<sub>30</sub> + IPC) in the absence or presence of the proteasome inhibitor lactacystin or the specific &#x003b5;PKC inhibitor &#x003b5;V<sub>1&#x02013;2</sub>. Chymotrypsin-like activity of the proteasome present in the cytoplasmic milieu was evaluated and the specific inhibitor MG-132 (20 &#x003bc;M) was utilized to ensure that measured activities were due to the proteasome (data not shown). The presence of unfolded proteins was evaluated using the slot blot technique with an anti-soluble oligomer antibody. Values representing ATP-dependent proteasome activity and misfolded proteins are presented as a percent of values obtained with samples from hearts exposed to 60 min of normoxic perfusion (N). Values represent the mean &#x000b1; standard deviation (<italic>n</italic> = 4). (<italic>B</italic>) Ischaemia resulted in a 50% decline in ATP-dependent proteasome activity (<italic>P</italic> &#x0003c; 0.05 vs. N), which was completely reversed by IPC (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>). The proteasome inhibitor, lactacystin (2 &#x003bc;M) and the specific &#x003b5;PKC inhibitor (1&#x003bc;M &#x003b5;V<sub>1&#x02013;2</sub>) both significantly decreased the activity of the proteasome (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub> + IPC; <italic>n</italic> = 4). (<italic>C</italic>) I<sub>30</sub>R<sub>60</sub> resulted in an &#x0223c;3-fold increase in misfolded proteins which was prevented by IPC (<italic>P</italic> &#x0003c; 0.05; <italic>n</italic> = 4). Treatment of hearts with lactacystin or &#x003b5;V<sub>1&#x02013;2</sub> blocked the effect of IPC and increased the accumulation of misfolded proteins. (<italic>D</italic>) IPC elevated ATP levels by 3.5-fold in hearts that had undergone I<sub>30</sub>R<sub>60,</sub> and &#x003b5;V<sub>1&#x02013;2</sub> blocked these effects. (<italic>E</italic>) Treatment with the &#x003b5;PKC activator (&#x003c8;&#x003b5;RACK) protected the proteasome from ischaemia-mediated inhibition (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>). *<italic>P</italic> &#x0003c; 0.05 vs. Normoxia, <sup>+</sup><italic>P</italic> = 0.05 vs. I<sub>30</sub>R<sub>60</sub>, &#x000a7;<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>, &#x02021;<italic>P</italic> &#x0003c; 0.05 vs. IPC + I<sub>30</sub>, &#x02020;<italic>P</italic> &#x0003c; 0.05 vs. IPC + I<sub>30</sub>R<sub>60</sub>; Misfolded protein accumulation and proteasome activity were analysed by one-way analysis of variance with a post-hoc Tukey test. <italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref>D</italic>, proteasome activity was analysed by Student's <italic>t</italic>-test.</p></caption><graphic xlink:href="cvp33403"/></fig><p>To determine if IPC increases proteasomal degradation of &#x003b4;PKC, we perfused the proteasome inhibitor, lactacystin (2 &#x003bc;M), during IPC and the first 10 min of reperfusion (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref>A</italic>). Lactacystin significantly blocked the activity of the proteasome (&#x0223c;75%; <italic>P</italic> &#x0003c; 0.01; <italic>n</italic> = 4; <italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref>B</italic>) and increased the levels of misfolded proteins by &#x0223c;7-fold (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref>C</italic>). In agreement with our findings in <italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F2">2</xref></italic>, IPC reduced post-reperfusion cellular levels of &#x003b4;PKC by &#x0223c;80% (<italic>P</italic> &#x0003c; 0.01; <italic>n</italic> = 4; <italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F4">4</xref>A</italic>). However, inhibition of the proteasome with lactacystin prevented the loss of &#x003b4;PKC after IPC and I<sub>30</sub>R<sub>60</sub> (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F4">4</xref>A</italic>). Although lactacystin treatment did not affect the levels of &#x003b5;PKC relative to IPC, the ratio of &#x003b5;PKC to &#x003b4;PKC decreased due to elevated levels of &#x003b4;PKC.</p><fig id="CVP334F4" position="float"><label>Figure&#x000a0;4</label><caption><p>Inhibition of the proteasome restores &#x003b4;PKC cellular and mitochondrial levels in IPC hearts with a resultant decrease in &#x003b5;PKC levels. (<italic>A</italic>) Hearts were hung in Langendorff mode and treated with the above-mentioned perfusion protocols. Hearts were then removed, homogenized, and the total homogenate and mitochondrial fractions were subjected to western blot analysis with antibodies against the proteins listed in the figure.&#x000a0;Values were normalized to GAPDH (total homogenate) or ANT (mitochondrial fraction) and expressed as % I<sub>30</sub>R<sub>60</sub>. IPC before prolonged ischaemia reduced total levels of &#x003b4;PKC by &#x0223c;80% (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub>). Inhibition of the proteasome with 2 &#x003bc;M lactacystin blocked &#x003b4;PKC degradation (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub> + IPC). Similar to <italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F2">2</xref></italic>, IPC before prolonged ischaemia did not significantly change overall levels of &#x003b5;PKC. However, inhibition of the proteasome increased &#x003b5;PKC levels by &#x0223c;2-folds (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub>). Inhibition of &#x003b5;PKC activity with &#x003b5;V<sub>1&#x02013;2</sub> did not significantly change the overall levels of either &#x003b4; or &#x003b5;PKC isozymes (data not shown). (<italic>B</italic>) As in <italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F2">2</xref></italic>, IPC before I<sub>30</sub>R<sub>60</sub> decreased levels of &#x003b4;PKC at mitochondria by &#x0223c;60% (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub>). This was completely prevented in hearts treated with 2 &#x003bc;M lactacystin and 1 &#x003bc;M &#x003b5;V<sub>1&#x02013;2</sub> (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub> + IPC). (<italic>C</italic>) Although &#x003b4;PKC mitochondrial levels were restored, &#x003b5;PKC levels were diminished by 40% relative to I<sub>30</sub>R<sub>60</sub> and by 60% relative to I<sub>30</sub>R<sub>60</sub> + IPC (<italic>P</italic> &#x0003c; 0.05). Hearts that were treated with 1 &#x003bc;M of a peptide inhibitor of &#x003b5;PKC (&#x003b5;V<sub>1&#x02013;2</sub>) during the IPC protocol showed a significant decrease in &#x003b5;PKC mitochondrial levels (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub> + IPC). *<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub>, &#x02021;<italic>P</italic> &#x0003c; 0.05 vs. IPC I<sub>30</sub>R<sub>60</sub>. Cellular and mitochondrial PKC levels were analysed by the one-way analysis of variance with a post-hoc testing by Tukey.</p></caption><graphic xlink:href="cvp33404"/></fig><p>Since lactacystin-mediated inhibition of the proteasome during IPC prevented &#x003b4;PKC degradation, it may promote translocation of &#x003b4;PKC to cardiac mitochondria. Indeed, lactacystin treatment completely blocked IPC-induced reductions in &#x003b4;PKC levels, restoring mitochondrial &#x003b4;PKC to levels obtained after I<sub>30</sub>/R<sub>60</sub> alone (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F4">4</xref>B</italic>). Interestingly, in contrast to the effects of proteasome inhibition on total &#x003b5;PKC levels, mitochondrial levels of &#x003b5;PKC were reduced by 50% in the presence of lactacystin (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F4">4</xref>C</italic>). These data suggest that IPC inversely affects the ratios of these two PKC isozymes at cardiac mitochondria following I/R likely through the regulation of proteasome activity. Additionally, lactacystin abolished IPC-mediated protection of ATP levels following ischaemia/reperfusion (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref>D</italic>).</p><p>We determined whether &#x003b5;PKC indirectly downregulates &#x003b4;PKC by protecting proteasomal function during IPC. To this end, we perfused the specific &#x003b5;PKC inhibitor, &#x003b5;V<sub>1&#x02013;2</sub><sup><xref ref-type="bibr" rid="CVP334C34">34</xref></sup> (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref>A</italic>) and found an &#x0223c;70% inhibition of proteasomal activity, an effect that was similar to that obtained by lactacystin (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref>B</italic>), and resulted in a corresponding increase in cellular misfolded proteins (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref>C</italic>). Similar to lactacystin, &#x003b5;V<sub>1&#x02013;2</sub> treatment significantly decreased &#x003b5;PKC levels at cardiac mitochondria (71% vs. IPC), and restored &#x003b4;PKC levels in this fraction (<italic>P</italic> &#x0003c; 0.05; <italic>n</italic> = 7) (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F4">4</xref>B</italic> and <italic>C</italic>). Perfusion with a specific &#x003b5;PKC activator, &#x003c8;&#x003b5;RACK, before ischaemia mimicked the IPC-mediated protective effect on proteasomal activity and prevented the loss in proteasomal activity seen during I/R (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref>E</italic>). This is likely an indirect effect, since &#x003b5;PKC was not found to associate with the proteasome following &#x003c8;&#x003b5;RACK treatment (data not shown).</p></sec><sec id="s3d"><label>3.4</label><title>Inhibition of the proteasome prevents Akt activation and increases release of cytochrome <italic>c</italic> during IPC</title><p>IPC activates the pro-survival kinases, Akt, and ERK1/2 and blocks cytochrome <italic>c</italic> release during reperfusion.<sup><xref ref-type="bibr" rid="CVP334C10">10</xref>,<xref ref-type="bibr" rid="CVP334C15">15</xref>,<xref ref-type="bibr" rid="CVP334C35">35</xref></sup> In contrast, &#x003b4;PKC decreases Akt activation and increases cytochrome <italic>c</italic> release during I/R.<sup><xref ref-type="bibr" rid="CVP334C2">2</xref></sup> Here we found that IPC significantly blocked I<sub>30</sub>/R<sub>60</sub> mediated release of mitochondrial cytochrome <italic>c</italic> into the cytosol (60%; <italic>P</italic> &#x0003c; 0.05; <italic>n</italic> = 4) (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F5">5</xref>A</italic>) and inhibition of the proteasome with lactacystin restored cytochrome <italic>c</italic> release to the levels seen during I<sub>30</sub>/R<sub>60</sub> (<italic>P</italic> &#x0003c; 0.05). Treatment of non-ischaemic hearts with either lactacystin or &#x003b5;V<sub>1&#x02013;2</sub> did not cause significant release of cytochrome <italic>c</italic> into the cytosol (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F5">5</xref>B</italic>). Additionally, IPC significantly increased the phosphorylation of the pro-survival kinase, Akt, over I<sub>30</sub>/R<sub>60</sub> levels (300%), and this was abolished by lactacystin treatment (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F5">5</xref>C</italic>). Li <italic>et al</italic>. showed that activation of &#x003b4;PKC reduces Akt phosphorylation whereas inhibition of &#x003b4;PKC increased Akt phosphorylation. They suggested that &#x003b4;PKC-mediated inhibition of Akt proceeds through increased association of protein phosphatase 2a.<sup><xref ref-type="bibr" rid="CVP334C36">36</xref></sup> Neither IPC nor lactacystin treatments significantly changed the phosphorylation levels of ERK-1/2 (not shown), consistent with the findings of other studies.<sup><xref ref-type="bibr" rid="CVP334C37">37</xref>,<xref ref-type="bibr" rid="CVP334C38">38</xref></sup></p><fig id="CVP334F5" position="float"><label>Figure&#x000a0;5</label><caption><p>Inhibition of &#x003b4;PKC degradation restores the apoptotic phenotype seen during reperfusion. Hearts were hung in Langendorff mode and treated with the listed perfusion protocols. Hearts were then removed, homogenized, fractionated, and the cytosolic homogenate was subjected to western blot analysis with antibodies against the proteins listed in the figure.&#x000a0;Values were normalized to GAPDH and expressed as % I<sub>30</sub>R<sub>60</sub>. (<italic>A</italic>) IPC before prolonged ischaemia significantly decreased cytochrome <italic>c</italic> release into the cytosol (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub>). Inhibition of the proteasome with 2 &#x003bc;M lactacystin restored cytochrome <italic>c</italic> release to levels seen during I<sub>30</sub>R<sub>60</sub> (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub> + IPC). (<italic>B</italic>) Ischaemia alone and perfusion with lactacystin or &#x003b5;V<sub>1&#x02013;2</sub> alone did not result in significant release of cytochrome <italic>c</italic> into the cytosol. Additionally, as evidenced by a lack of mitochondrial VDAC in the cytosolic fraction, there was little contamination from mitochondrial cytochrome <italic>c</italic> in this fraction. Enolase was used as a cytosolic loading control. (<italic>C</italic>) IPC before prolonged ischaemia also increased phosphorylation of the pro-survival kinase, Akt, by &#x0223c;3-fold (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub>). Inhibition of the proteasome with 2 &#x003bc;M lactacystin decreased phosphorylation back to I<sub>30</sub>R<sub>60</sub> levels (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub> + IPC). *<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub>, &#x02021;<italic>P</italic> &#x0003c; 0.05 vs. IPC I<sub>30</sub>R<sub>60</sub>. Cytosolic cytochrome <italic>c</italic> levels and p-Akt were analysed by one-way analysis of variance with a post-hoc Tukey test.</p></caption><graphic xlink:href="cvp33405"/></fig></sec><sec id="s3e"><label>3.5</label><title>Inhibition of the proteasome during IPC increases tissue injury</title><p>Since pharmacological inhibition of the proteasome during IPC restored the apoptotic phenotype, we determined if tissue injury is altered by proteasome inhibition. As reported, IPC decreased both creatine phosphokinase (CPK) release and tetrazolium tetrachloride (TTC) staining of the myocardium by &#x0223c;70 and 60%, respectively (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F6">6</xref>A and B</italic>) and Lactacystin reversed the benefits of IPC-mediated protection. As we found before in isolated myocytes,<sup><xref ref-type="bibr" rid="CVP334C28">28</xref></sup> in addition to the effects of &#x003b5;V<sub>1&#x02013;2</sub> on proteasomal function and &#x003b4;PKC translocation, inhibition of &#x003b5;PKC also completely reversed the protective effects of IPC on the myocardium (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F6">6</xref>A and B</italic>). Finally, to confirm the effects of lactacystin, we utilized another highly selective inhibitor of the proteasome, epoxomicin. Similar to lactacystin, inhibition of the proteasome with epoxomicin (2 &#x003bc;M) abolished the cardioprotective effects of IPC (data not shown).</p><fig id="CVP334F6" position="float"><label>Figure&#x000a0;6</label><caption><p>Inhibition of the proteasome reverses the IPC-mediated protective effects on tissue injury. Hearts were hung in Langendorff mode and treated with the listed perfusion protocols. Tissue injury was determined by measuring the release of CPK into the cardiac effluent (total CPK units). Following removal, hearts were sliced and stained with TTC to differentiate between necrotic (stained white) and viable (stained red) tissue (% infarct). (<italic>A,B</italic>) Hearts subjected to I<sub>30</sub>R<sub>60</sub> showed an increase in both CPK release and myocardial infarction and both were blocked by IPC (reductions of &#x0223c;60% for CPK release and &#x0223c;40% for infarction, respectively). Perfusion of 2 &#x003bc;M lactacystin during the IPC protocol and for the first 10 min of reperfusion reversed this effect resulting in significantly higher levels of CPK release (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub> + IPC) and myocardial infarction (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub> + IPC). Similar to proteasome inhibition, &#x003b5;PKC inhibition (1 &#x003bc;M &#x003b5;V<sub>1&#x02013;2</sub>) also significantly increased both CPK release (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub> + IPC) and myocardial infarction (<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub> + IPC). *<italic>P</italic> &#x0003c; 0.05 vs. I<sub>30</sub>R<sub>60</sub>, &#x02021;<italic>P</italic> &#x0003c; 0.05 vs. IPC I<sub>30</sub>R<sub>60</sub>. Total CPK and % infarcted area were analysed by the one-way analysis of variance with a post-hoc Tukey test.</p></caption><graphic xlink:href="cvp33406"/></fig></sec></sec><sec id="s4" sec-type="discussion"><label>4.</label><title>Discussion</title><p>Our data suggest that IPC-induced decreases in mitochondrial &#x003b4;PKC levels are due to decreased total levels of &#x003b4;PKC. We also show that IPC prevents ischaemia-mediated declines in the 26S ATP-dependant proteasomal activity and that this is associated with diminished accumulation of cellular misfolded proteins. Ischaemia-mediated declines in forebrain ATP levels promote dissociation of the 26S proteasome (the form responsible for &#x003b4;PKC degradation<sup><xref ref-type="bibr" rid="CVP334C29">29</xref></sup>) to the 20S proteasome.<sup><xref ref-type="bibr" rid="CVP334C32">32</xref></sup> During I/R, (in the absence of preconditioning) the significant decrease in ATP-dependent proteasomal activity is therefore likely due to decreased ATP levels within the cells. Indeed, as has been shown before,<sup><xref ref-type="bibr" rid="CVP334C4">4</xref>,<xref ref-type="bibr" rid="CVP334C39">39</xref></sup> and here in an <italic>ex vivo</italic> model of ischaemia/reperfusion, ATP levels significantly declined during ischaemia/reperfusion and IPC significantly prevented this decline (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref>D</italic>). Alternatively, modifications by lipid peroxidation products and accumulation of oxidized proteins during I/R may also act as inhibitors of proteasomal function.<sup><xref ref-type="bibr" rid="CVP334C40">40</xref></sup> Inhibition of the proteasome with lactacystin or epoxomicin blocked the protective effects of IPC. Additionally, lactacystin treatment elevated &#x003b4;PKC cellular and mitochondrial levels, and promoted cytochrome <italic>c</italic> release. &#x003b4;PKC is ubiquitinated within 30 min of activation<sup><xref ref-type="bibr" rid="CVP334C41">41</xref></sup> and direct inhibition of the 26S proteasome with Bortezomib, a highly selective proteasome inhibitor currently in clinical use for the treatment of haematological cancers, increases mitochondrial ROS generation, cytochrome <italic>c</italic> release, and apoptosis associated with mitochondrial accumulation of &#x003b4;PKC.<sup><xref ref-type="bibr" rid="CVP334C29">29</xref>,<xref ref-type="bibr" rid="CVP334C42">42</xref></sup> We suggest that since IPC and &#x003b5;PKC activation slow ATP depletion during prolonged ischaemia<sup><xref ref-type="bibr" rid="CVP334C8">8</xref>,<xref ref-type="bibr" rid="CVP334C43">43</xref></sup> and &#x003b4;PKC is likely activated by the IPC stimulus (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F1">1</xref>C</italic>)<sup><xref ref-type="bibr" rid="CVP334C3">3</xref></sup> the 26S proteasomal activity is maintained leading to the degradation of pro-apoptotic and pro-necrotic, &#x003b4;PKC,<sup><xref ref-type="bibr" rid="CVP334C2">2</xref>,<xref ref-type="bibr" rid="CVP334C4">4</xref></sup> thereby conferring cardiac protection. Although the most likely explanation for the decrease in &#x003b4;PKC levels in the mitochondria is a decrease in total level of this isozyme in the cells (due to its increased degradation by the proteasome), we cannot exclude the possibility that decreased affinity of the binding site for &#x003b4;PKC in the mitochondria and post-translational modifications of the enzyme or its binding proteins also contribute to &#x003b4;PKC declined levels and therefore activity in the mitochondria. We have previously shown that accumulation of &#x003b4;PKC at cardiac mitochondria increases PDH phosphorylation and the inhibitor &#x003b4;V<sub>1&#x02013;1</sub> prevents this.<sup><xref ref-type="bibr" rid="CVP334C3">3</xref></sup> Additionally, we have shown that &#x003b5;PKC is able to activate ALDH2 in hearts in the same <italic>in vivo</italic> model of I/R.<sup><xref ref-type="bibr" rid="CVP334C44">44</xref></sup> Therefore, we have already provided direct evidence in this model of I/R that increased levels of PKC isozymes in the mitochondrial fraction are associated with increased phosphorylation of target substrates and hence reflect increased catalytic activity of these isozymes.</p><p>In addition to the protection afforded by degrading &#x003b4;PKC, increased &#x003b5;PKC accumulation at cardiac mitochondria is also likely to confer protection. &#x003b5;PKC translocates to mitochondria,<sup><xref ref-type="bibr" rid="CVP334C16">16</xref>,<xref ref-type="bibr" rid="CVP334C19">19</xref>&#x02013;<xref ref-type="bibr" rid="CVP334C22">22</xref></sup> where it prevents opening of the mitochondrial permeability transition pore,<sup><xref ref-type="bibr" rid="CVP334C19">19</xref>,<xref ref-type="bibr" rid="CVP334C45">45</xref></sup> opens kATP channels,<sup><xref ref-type="bibr" rid="CVP334C9">9</xref></sup> forms signalling complexes with MAPK,<sup><xref ref-type="bibr" rid="CVP334C9">9</xref></sup> retards the reduction in cellular ATP levels,<sup><xref ref-type="bibr" rid="CVP334C46">46</xref></sup> interacts with the electron transport chain,<sup><xref ref-type="bibr" rid="CVP334C47">47</xref></sup> and augments mitochondrial function<sup><xref ref-type="bibr" rid="CVP334C39">39</xref></sup> all of which contribute to cardioprotection. Since the relative level of &#x003b5;PKC at the mitochondria during reperfusion in the absence of the IPC stimulus is similar to &#x003b4;PKC levels, &#x003b5;PKC-mediated cardioprotection may be masked by the pro-apoptotic and pro-necrotic effects of &#x003b4;PKC during reperfusion. Administration of the &#x003b5;PKC activator, &#x003c8;&#x003b5;RACK, prior to ischaemia, which mimics IPC and protects mitochondrial function<sup><xref ref-type="bibr" rid="CVP334C39">39</xref></sup> prevented ischaemia-mediated declines in proteasome activity. Although recent studies suggest that kinases may regulate proteasome function directly,<sup><xref ref-type="bibr" rid="CVP334C48">48</xref></sup> we did not find any physical association between &#x003b5;PKC and the proteasome.</p><p>In summary, activated &#x003b4;PKC has two potential fates that appear to depend on the metabolic state of the cell. If mitochondrial function, cellular energy status, and the integrity of the 26S proteasome are maintained, &#x003b4;PKC is efficiently degraded. In contrast, if mitochondrial function and ATP production are compromised, the ATP-dependent 26S proteasome activity is diminished, resulting in increased levels of activated &#x003b4;PKC at the mitochondria, where it participates in the induction of cell death. The proteasome can therefore be viewed as a sensor of cellular viability, determining the ratio of pro-apoptotic &#x003b4;PKC and pro-survival &#x003b5;PKC at the mitochondria and thus the ultimate fate of the cell. We propose the following mechanism. The decrease in ATP levels seen during I/R (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref>D</italic>) and increased generation of reactive oxygen species, will diminish 26S proteasome activity.<sup><xref ref-type="bibr" rid="CVP334C40">40</xref></sup> &#x003b4;PKC is activated by ROS<sup><xref ref-type="bibr" rid="CVP334C4">4</xref></sup> and also during the early stages of reperfusion, resulting in its accumulation at cardiac mitochondria (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F1">1</xref></italic>).<sup><xref ref-type="bibr" rid="CVP334C3">3</xref></sup> Because the activity of the proteasome is diminished (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref></italic>), &#x003b4;PKC is not degraded, favouring its accumulation at cardiac mitochondria (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F4">4</xref></italic>), where it triggers pro-apoptotic cytochrome <italic>c</italic> release and inactivation of Akt (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F5">5</xref></italic>), leading to tissue injury (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F6">6</xref></italic>). In contrast, IPC is associated with a small burst of mitochondrial ROS during the trigger phase of IPC, which decreases ROS generation during the effector phase<sup><xref ref-type="bibr" rid="CVP334C49">49</xref></sup> and may also act as a stimulus for &#x003b4;PKC activation (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F1">1</xref>C</italic>). Diminished ROS generation and maintenance of cellular ATP levels (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F3">3</xref>D</italic>) result in protection of proteasomal function,<sup><xref ref-type="bibr" rid="CVP334C50">50</xref></sup> which leads to degradation of &#x003b4;PKC (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F4">4</xref>A</italic>). Since both &#x003b5;PKC and &#x003b4;PKC accumulate at the mitochondria during I<sub>30</sub>R<sub>60</sub> (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F1">1</xref>B</italic>) and since &#x003b5;PKC is not degraded during I<sub>30</sub>R<sub>60</sub> (<italic>Figure&#x000a0;<xref ref-type="fig" rid="CVP334F2">2</xref>A</italic>), degradation of &#x003b4;PKC during IPC tips the balance towards the accumulation of the pro-survival kinase, &#x003b5;PKC, at cardiac mitochondria, thus protecting mitochondrial function and proteasomal activity thereby diminishing I/R-mediated tissue injury.</p><p><bold>Conflict of interest:</bold> D.M.-R. is the founder of KAI Pharmaceuticals. However, none of the work described in the study is based on or supported by the company.</p></sec><sec id="s5"><title>Funding</title><p><funding-source>NIH</funding-source><award-id>AA11147</award-id> to D.M.-R., <funding-source>Oklahoma Center for Advancement of Science and Technology</funding-source> (<award-id>HR05-171S</award-id>) to L.I.S. Funding to pay the Open Access publication charges for this article was provided by Dr Mochly-Rosen's unrestricted funding source (no grant was used).</p></sec></body><back><ref-list><title>References</title><ref id="CVP334C1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buja</surname><given-names>LM</given-names></name><name><surname>Entman</surname><given-names>ML</given-names></name></person-group><article-title>Modes of myocardial cell injury and cell death in ischemic heart disease</article-title><source>Circulation</source><year>1998</year><volume>98</volume><fpage>1355</fpage><lpage>1357</lpage><pub-id pub-id-type="pmid">9760287</pub-id></element-citation></ref><ref id="CVP334C2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murriel</surname><given-names>CL</given-names></name><name><surname>Churchill</surname><given-names>E</given-names></name><name><surname>Inagaki</surname><given-names>K</given-names></name><name><surname>Szweda</surname><given-names>LI</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>Protein kinase Cdelta activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving BAD and the mitochondria</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>47985</fpage><lpage>47991</lpage><pub-id pub-id-type="pmid">15339931</pub-id></element-citation></ref><ref id="CVP334C3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Churchill</surname><given-names>EN</given-names></name><name><surname>Murriel</surname><given-names>CL</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name><name><surname>Szweda</surname><given-names>LI</given-names></name></person-group><article-title>Reperfusion-induced translocation of deltaPKC to cardiac mitochondria prevents pyruvate dehydrogenase reactivation</article-title><source>Circ Res</source><year>2005</year><volume>97</volume><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">15961716</pub-id></element-citation></ref><ref id="CVP334C4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Ikeno</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>FH</given-names></name><name><surname>Imahashi</surname><given-names>K</given-names></name><name><surname>Bouley</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo</article-title><source>Circulation</source><year>2003</year><volume>108</volume><fpage>2304</fpage><lpage>2307</lpage><pub-id pub-id-type="pmid">14597593</pub-id></element-citation></ref><ref id="CVP334C5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><etal/></person-group><source>Opposing cardioprotective actions and parallel hypertrophic effects of &#x003b4; and &#x003b5;PKC. Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>11114</fpage><lpage>11119</lpage></element-citation></ref><ref id="CVP334C6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yellon</surname><given-names>DM</given-names></name><name><surname>Alkhulaifi</surname><given-names>AM</given-names></name><name><surname>Pugsley</surname><given-names>WB</given-names></name></person-group><article-title>Preconditioning the human myocardium</article-title><source>Lancet</source><year>1993</year><volume>342</volume><fpage>276</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">8101304</pub-id></element-citation></ref><ref id="CVP334C7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>GS</given-names></name><name><surname>Thornton</surname><given-names>J</given-names></name><name><surname>Van Winkle</surname><given-names>DM</given-names></name><name><surname>Stanley</surname><given-names>AW</given-names></name><name><surname>Olsson</surname><given-names>RA</given-names></name><name><surname>Downey</surname><given-names>JM</given-names></name></person-group><article-title>Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart</article-title><source>Circulation</source><year>1991</year><volume>84</volume><fpage>350</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">2060105</pub-id></element-citation></ref><ref id="CVP334C8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murry</surname><given-names>CE</given-names></name><name><surname>Jennings</surname><given-names>RB</given-names></name><name><surname>Reimer</surname><given-names>KA</given-names></name></person-group><article-title>Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium</article-title><source>Circulation</source><year>1986</year><volume>74</volume><fpage>1124</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">3769170</pub-id></element-citation></ref><ref id="CVP334C9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baines</surname><given-names>CP</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>GW</given-names></name><name><surname>Zheng</surname><given-names>YT</given-names></name><name><surname>Xiu</surname><given-names>JX</given-names></name><name><surname>Cardwell</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon&#x02013;MAPK interactions and differential MAPK activation in PKCepsilon-induced cardioprotection</article-title><source>Circ Res</source><year>2002</year><volume>90</volume><fpage>390</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">11884367</pub-id></element-citation></ref><ref id="CVP334C10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><name><surname>Tsang</surname><given-names>A</given-names></name><name><surname>Mocanu</surname><given-names>MM</given-names></name><name><surname>Yellon</surname><given-names>DM</given-names></name></person-group><article-title>Ischemic preconditioning protects by activating prosurvival kinases at reperfusion</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2005</year><volume>288</volume><fpage>H971</fpage><lpage>H976</lpage><pub-id pub-id-type="pmid">15358610</pub-id></element-citation></ref><ref id="CVP334C11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solenkova</surname><given-names>NV</given-names></name><name><surname>Solodushko</surname><given-names>V</given-names></name><name><surname>Cohen</surname><given-names>MV</given-names></name><name><surname>Downey</surname><given-names>JM</given-names></name></person-group><article-title>Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2006</year><volume>290</volume><fpage>H441</fpage><lpage>H449</lpage><pub-id pub-id-type="pmid">16155103</pub-id></element-citation></ref><ref id="CVP334C12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>McPherson</surname><given-names>BC</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name></person-group><article-title>Preconditioning attenuates apoptosis and necrosis: role of protein kinase C epsilon and -delta isoforms</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2001</year><volume>281</volume><fpage>H404</fpage><lpage>H410</lpage><pub-id pub-id-type="pmid">11406509</pub-id></element-citation></ref><ref id="CVP334C13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Hirai</surname><given-names>K</given-names></name><name><surname>Ayub</surname><given-names>A</given-names></name><name><surname>Ashraf</surname><given-names>M</given-names></name></person-group><article-title>Calcium preconditioning inhibits mitochondrial permeability transition and apoptosis</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2001</year><volume>280</volume><fpage>H899</fpage><lpage>H908</lpage><pub-id pub-id-type="pmid">11158992</pub-id></element-citation></ref><ref id="CVP334C14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausenloy</surname><given-names>D</given-names></name><name><surname>Wynne</surname><given-names>A</given-names></name><name><surname>Duchen</surname><given-names>M</given-names></name><name><surname>Yellon</surname><given-names>D</given-names></name></person-group><article-title>Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>1714</fpage><lpage>1717</lpage><pub-id pub-id-type="pmid">15066952</pub-id></element-citation></ref><ref id="CVP334C15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundberg</surname><given-names>KC</given-names></name><name><surname>Szweda</surname><given-names>LI</given-names></name></person-group><article-title>Preconditioning prevents loss in mitochondrial function and release of cytochrome c during prolonged cardiac ischemia/reperfusion</article-title><source>Arch Biochem Biophys</source><year>2006</year><volume>453</volume><fpage>130</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">16546113</pub-id></element-citation></ref><ref id="CVP334C16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Chun</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>CH</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name></person-group><article-title>Ischemic preconditioning reduces Op6 generation and prevents respiratory impairment in the mitochondria of post-ischemic reperfused heart of rat</article-title><source>Life Sci</source><year>1997</year><volume>60</volume><fpage>2207</fpage><lpage>2219</lpage><pub-id pub-id-type="pmid">9188764</pub-id></element-citation></ref><ref id="CVP334C17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaburek</surname><given-names>M</given-names></name><name><surname>Costa</surname><given-names>AD</given-names></name><name><surname>Burton</surname><given-names>JR</given-names></name><name><surname>Costa</surname><given-names>CL</given-names></name><name><surname>Garlid</surname><given-names>KD</given-names></name></person-group><article-title>Mitochondrial PKC epsilon and mitochondrial ATP-sensitive K+ channel copurify and coreconstitute to form a functioning signaling module in proteoliposomes</article-title><source>Circ Res</source><year>2006</year><volume>99</volume><fpage>878</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">16960097</pub-id></element-citation></ref><ref id="CVP334C18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohnuma</surname><given-names>Y</given-names></name><name><surname>Miura</surname><given-names>T</given-names></name><name><surname>Miki</surname><given-names>T</given-names></name><name><surname>Tanno</surname><given-names>M</given-names></name><name><surname>Kuno</surname><given-names>A</given-names></name><name><surname>Tsuchida</surname><given-names>A</given-names></name><etal/></person-group><article-title>Opening of mitochondrial K(ATP) channel occurs downstream of PKC-epsilon activation in the mechanism of preconditioning</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2002</year><volume>283</volume><fpage>H440</fpage><lpage>H447</lpage><pub-id pub-id-type="pmid">12063319</pub-id></element-citation></ref><ref id="CVP334C19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baines</surname><given-names>CP</given-names></name><name><surname>Song</surname><given-names>CX</given-names></name><name><surname>Zheng</surname><given-names>YT</given-names></name><name><surname>Wang</surname><given-names>GW</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>OL</given-names></name><etal/></person-group><article-title>Protein kinase Cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria</article-title><source>Circ Res</source><year>2003</year><volume>92</volume><fpage>873</fpage><lpage>880</lpage><pub-id pub-id-type="pmid">12663490</pub-id></element-citation></ref><ref id="CVP334C20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogbi</surname><given-names>M</given-names></name><name><surname>Chew</surname><given-names>CS</given-names></name><name><surname>Pohl</surname><given-names>J</given-names></name><name><surname>Stuchlik</surname><given-names>O</given-names></name><name><surname>Ogbi</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>JA</given-names></name></person-group><article-title>Cytochrome c oxidase subunit IV as a marker of protein kinase Cepsilon function in neonatal cardiac myocytes: implications for cytochrome c oxidase activity</article-title><source>Biochem J</source><year>2004</year><volume>382</volume><fpage>923</fpage><lpage>932</lpage><pub-id pub-id-type="pmid">15339253</pub-id></element-citation></ref><ref id="CVP334C21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ytrehus</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Downey</surname><given-names>JM</given-names></name></person-group><article-title>Preconditioning protects ischemic rabbit heart by protein kinase C activation</article-title><source>Am J Physiol</source><year>1994</year><volume>266</volume><fpage>H1145</fpage><lpage>H1152</lpage><pub-id pub-id-type="pmid">8160817</pub-id></element-citation></ref><ref id="CVP334C22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fryer</surname><given-names>RM</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Hsu</surname><given-names>AK</given-names></name><name><surname>Gross</surname><given-names>GJ</given-names></name></person-group><article-title>Essential activation of PKC-delta in opioid-initiated cardioprotection</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2001</year><volume>280</volume><fpage>H1346</fpage><lpage>H1353</lpage><pub-id pub-id-type="pmid">11179083</pub-id></element-citation></ref><ref id="CVP334C23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamura</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Miura</surname><given-names>T</given-names></name><name><surname>Mizukami</surname><given-names>Y</given-names></name><name><surname>Matsuzaki</surname><given-names>M</given-names></name></person-group><article-title>Ischemic preconditioning translocates PKC-delta and -epsilon, which mediate functional protection in isolated rat heart</article-title><source>Am J Physiol</source><year>1998</year><volume>275</volume><fpage>H2266</fpage><lpage>H2271</lpage><pub-id pub-id-type="pmid">9843828</pub-id></element-citation></ref><ref id="CVP334C24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Renner</surname><given-names>O</given-names></name><name><surname>Wightman</surname><given-names>L</given-names></name><name><surname>Sugden</surname><given-names>PH</given-names></name><name><surname>Stewart</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>AD</given-names></name><etal/></person-group><article-title>The expression of constitutively active isotypes of protein kinase C to investigate preconditioning</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>23072</fpage><lpage>23079</lpage><pub-id pub-id-type="pmid">9722533</pub-id></element-citation></ref><ref id="CVP334C25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname><given-names>K</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>DeltaPKC-mediated activation of epsilonPKC in ethanol-induced cardiac protection from ischemia</article-title><source>J Mol Cell Cardiol</source><year>2005</year><volume>39</volume><fpage>203</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">15990110</pub-id></element-citation></ref><ref id="CVP334C26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabir</surname><given-names>AM</given-names></name><name><surname>Clark</surname><given-names>JE</given-names></name><name><surname>Tanno</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Hothersall</surname><given-names>JS</given-names></name><name><surname>Dashnyam</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cardioprotection initiated by reactive oxygen species is dependent on activation of PKC{varepsilon}</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2006</year><volume>291</volume><fpage>H1893</fpage><lpage>H1899</lpage><pub-id pub-id-type="pmid">16714357</pub-id></element-citation></ref><ref id="CVP334C27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayr</surname><given-names>M</given-names></name><name><surname>Metzler</surname><given-names>B</given-names></name><name><surname>Chung</surname><given-names>YL</given-names></name><name><surname>McGregor</surname><given-names>E</given-names></name><name><surname>Mayr</surname><given-names>U</given-names></name><name><surname>Troy</surname><given-names>H</given-names></name><etal/></person-group><article-title>Ischemic preconditioning exaggerates cardiac damage in PKC-delta null mice</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2004</year><volume>287</volume><fpage>H946</fpage><lpage>H956</lpage><pub-id pub-id-type="pmid">15277209</pub-id></element-citation></ref><ref id="CVP334C28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>MO</given-names></name><name><surname>Karliner</surname><given-names>JS</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>30945</fpage><lpage>30951</lpage><pub-id pub-id-type="pmid">9388241</pub-id></element-citation></ref><ref id="CVP334C29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durrant</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>RM</given-names></name></person-group><article-title>The bortezomib-induced mitochondrial damage is mediated by accumulation of active protein kinase C-delta</article-title><source>Biochem Biophys Res Commun</source><year>2004</year><volume>321</volume><fpage>905</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">15358112</pub-id></element-citation></ref><ref id="CVP334C30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Churchill</surname><given-names>EN</given-names></name><name><surname>Disatnik</surname><given-names>MH</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>Time-dependent and ethanol-induced cardiac protection from ischemia mediated by mitochondrial translocation of varepsilonPKC and activation of aldehyde dehydrogenase 2</article-title><source>J Mol Cell Cardiol</source><year>2009</year><volume>46</volume><fpage>278</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">18983847</pub-id></element-citation></ref><ref id="CVP334C31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanbe</surname><given-names>A</given-names></name><name><surname>Osinska</surname><given-names>H</given-names></name><name><surname>Villa</surname><given-names>C</given-names></name><name><surname>Gulick</surname><given-names>J</given-names></name><name><surname>Klevitsky</surname><given-names>R</given-names></name><name><surname>Glabe</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>13592</fpage><lpage>13597</lpage><pub-id pub-id-type="pmid">16155124</pub-id></element-citation></ref><ref id="CVP334C32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asai</surname><given-names>A</given-names></name><name><surname>Tanahashi</surname><given-names>N</given-names></name><name><surname>Qiu</surname><given-names>JH</given-names></name><name><surname>Saito</surname><given-names>N</given-names></name><name><surname>Chi</surname><given-names>S</given-names></name><name><surname>Kawahara</surname><given-names>N</given-names></name><etal/></person-group><article-title>Selective proteasomal dysfunction in the hippocampal CA1 region after transient forebrain ischemia</article-title><source>J Cereb Blood Flow Metab</source><year>2002</year><volume>22</volume><fpage>705</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">12045669</pub-id></element-citation></ref><ref id="CVP334C33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fralix</surname><given-names>TA</given-names></name><name><surname>Murphy</surname><given-names>E</given-names></name><name><surname>London</surname><given-names>RE</given-names></name><name><surname>Steenbergen</surname><given-names>C</given-names></name></person-group><article-title>Protective effects of adenosine in the perfused rat heart: changes in metabolism and intracellular ion homeostasis</article-title><source>Am J Physiol</source><year>1993</year><volume>264</volume><fpage>C986</fpage><lpage>C994</lpage><pub-id pub-id-type="pmid">8476025</pub-id></element-citation></ref><ref id="CVP334C34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JA</given-names></name><name><surname>Gray</surname><given-names>MO</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>24962</fpage><lpage>24966</lpage><pub-id pub-id-type="pmid">8798776</pub-id></element-citation></ref><ref id="CVP334C35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchiyama</surname><given-names>T</given-names></name><name><surname>Engelman</surname><given-names>RM</given-names></name><name><surname>Maulik</surname><given-names>N</given-names></name><name><surname>Das</surname><given-names>DK</given-names></name></person-group><article-title>Role of Akt signaling in mitochondrial survival pathway triggered by hypoxic preconditioning</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>3042</fpage><lpage>3049</lpage><pub-id pub-id-type="pmid">15184284</pub-id></element-citation></ref><ref id="CVP334C36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Sampat</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>N</given-names></name><name><surname>Zakari</surname><given-names>J</given-names></name><name><surname>Yuspa</surname><given-names>SH</given-names></name></person-group><article-title>Protein kinase c negatively regulates Akt activity and modifies UVC-induced apoptosis in mouse keratinocytes</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>3237</fpage><lpage>3243</lpage><pub-id pub-id-type="pmid">16338928</pub-id></element-citation></ref><ref id="CVP334C37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behrends</surname><given-names>M</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>Post</surname><given-names>H</given-names></name><name><surname>Alexandrov</surname><given-names>A</given-names></name><name><surname>Belosjorow</surname><given-names>S</given-names></name><name><surname>Michel</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Inconsistent relation of MAPK activation to infarct size reduction by ischemic preconditioning in pigs</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2000</year><volume>279</volume><fpage>H1111</fpage><lpage>H1119</lpage><pub-id pub-id-type="pmid">10993774</pub-id></element-citation></ref><ref id="CVP334C38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mockridge</surname><given-names>JW</given-names></name><name><surname>Punn</surname><given-names>A</given-names></name><name><surname>Latchman</surname><given-names>DS</given-names></name><name><surname>Marber</surname><given-names>MS</given-names></name><name><surname>Heads</surname><given-names>RJ</given-names></name></person-group><article-title>PKC-dependent delayed metabolic preconditioning is independent of transient MAPK activation</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2000</year><volume>279</volume><fpage>H492</fpage><lpage>H501</lpage><pub-id pub-id-type="pmid">10924046</pub-id></element-citation></ref><ref id="CVP334C39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>J</given-names></name><name><surname>McLeod</surname><given-names>CJ</given-names></name><name><surname>Minners</surname><given-names>J</given-names></name><name><surname>Essop</surname><given-names>MF</given-names></name><name><surname>Ping</surname><given-names>P</given-names></name><name><surname>Sack</surname><given-names>MN</given-names></name></person-group><article-title>PKCepsilon activation augments cardiac mitochondrial respiratory post-anoxic reserve&#x02014;a putative mechanism in PKCepsilon cardioprotection</article-title><source>J Mol Cell Cardiol</source><year>2005</year><volume>38</volume><fpage>697</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">15808847</pub-id></element-citation></ref><ref id="CVP334C40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulteau</surname><given-names>AL</given-names></name><name><surname>Lundberg</surname><given-names>KC</given-names></name><name><surname>Humphries</surname><given-names>KM</given-names></name><name><surname>Sadek</surname><given-names>HA</given-names></name><name><surname>Szweda</surname><given-names>PA</given-names></name><name><surname>Friguet</surname><given-names>B</given-names></name><etal/></person-group><article-title>Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>30057</fpage><lpage>30063</lpage><pub-id pub-id-type="pmid">11375979</pub-id></element-citation></ref><ref id="CVP334C41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Hornia</surname><given-names>A</given-names></name><name><surname>Devonish</surname><given-names>W</given-names></name><name><surname>Pagano</surname><given-names>M</given-names></name><name><surname>Foster</surname><given-names>DA</given-names></name></person-group><article-title>Activation of protein kinase C triggers its ubiquitination and degradation</article-title><source>Mol Cell Biol</source><year>1998</year><volume>18</volume><fpage>839</fpage><lpage>845</lpage><pub-id pub-id-type="pmid">9447980</pub-id></element-citation></ref><ref id="CVP334C42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>YH</given-names></name><name><surname>Liebes</surname><given-names>L</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Perez-Soler</surname><given-names>R</given-names></name></person-group><article-title>Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>33714</fpage><lpage>33723</lpage><pub-id pub-id-type="pmid">12821677</pub-id></element-citation></ref><ref id="CVP334C43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murry</surname><given-names>CE</given-names></name><name><surname>Richard</surname><given-names>VJ</given-names></name><name><surname>Reimer</surname><given-names>KA</given-names></name><name><surname>Jennings</surname><given-names>RB</given-names></name></person-group><article-title>Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode</article-title><source>Circ Res</source><year>1990</year><volume>66</volume><fpage>913</fpage><lpage>931</lpage><pub-id pub-id-type="pmid">2317895</pub-id></element-citation></ref><ref id="CVP334C44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Budas</surname><given-names>GR</given-names></name><name><surname>Churchill</surname><given-names>EN</given-names></name><name><surname>Disatnik</surname><given-names>MH</given-names></name><name><surname>Hurley</surname><given-names>TD</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart</article-title><source>Science</source><year>2008</year><volume>321</volume><fpage>1493</fpage><lpage>1495</lpage><pub-id pub-id-type="pmid">18787169</pub-id></element-citation></ref><ref id="CVP334C45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ping</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Pierce</surname><given-names>WM</given-names><suffix>Jr</suffix></name><name><surname>Bolli</surname><given-names>R</given-names></name></person-group><article-title>Functional proteomic analysis of protein kinase C epsilon signaling complexes in the normal heart and during cardioprotection</article-title><source>Circ Res</source><year>2001</year><volume>88</volume><fpage>59</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">11139474</pub-id></element-citation></ref><ref id="CVP334C46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>HR</given-names></name><name><surname>Murphy</surname><given-names>E</given-names></name><name><surname>Bolli</surname><given-names>R</given-names></name><name><surname>Ping</surname><given-names>P</given-names></name><name><surname>Steenbergen</surname><given-names>C</given-names></name></person-group><article-title>Expression of activated PKC epsilon (PKC epsilon) protects the ischemic heart, without attenuating ischemic H(+) production</article-title><source>J Mol Cell Cardiol</source><year>2002</year><volume>34</volume><fpage>361</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">11945027</pub-id></element-citation></ref><ref id="CVP334C47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Ogbi</surname><given-names>M</given-names></name><name><surname>Caldwell</surname><given-names>RWP</given-names></name><name><surname>Johnson</surname><given-names>JA</given-names></name></person-group><article-title>Differential loss of cytochrome c oxidase (CO) subunits in ischemia reperfusion injury: exacerbation of COI loss by {varepsilon}PKC inhibition</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2008</year><volume>294</volume><fpage>H2637</fpage><lpage>H2645</lpage><pub-id pub-id-type="pmid">18408135</pub-id></element-citation></ref><ref id="CVP334C48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zong</surname><given-names>C</given-names></name><name><surname>Gomes</surname><given-names>AV</given-names></name><name><surname>Drews</surname><given-names>O</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Young</surname><given-names>GW</given-names></name><name><surname>Berhane</surname><given-names>B</given-names></name><etal/></person-group><article-title>Regulation of murine cardiac 20S proteasomes: role of associating partners</article-title><source>Circ Res</source><year>2006</year><volume>99</volume><fpage>372</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">16857963</pub-id></element-citation></ref><ref id="CVP334C49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baines</surname><given-names>CP</given-names></name><name><surname>Goto</surname><given-names>M</given-names></name><name><surname>Downey</surname><given-names>JM</given-names></name></person-group><article-title>Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium</article-title><source>J Mol Cell Cardiol</source><year>1997</year><volume>29</volume><fpage>207</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">9040035</pub-id></element-citation></ref><ref id="CVP334C50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>SR</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Katzeff</surname><given-names>H</given-names></name><name><surname>Shringarpure</surname><given-names>R</given-names></name><name><surname>Teoh</surname><given-names>C</given-names></name><name><surname>Khaliulin</surname><given-names>I</given-names></name><name><surname>Das</surname><given-names>DK</given-names></name><name><surname>Davies</surname><given-names>KJ</given-names></name><name><surname>Schwalb</surname><given-names>H</given-names></name></person-group><article-title>Oxidized and ubiquitinated proteins may predict recovery of postischemic cardiac function: essential role of the proteasome</article-title><source>Antioxid Redox Signal</source><year>2005</year><volume>7</volume><fpage>538</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">15889999</pub-id></element-citation></ref></ref-list></back></article>